Long-acting GLP-1 drug TE-8105, developed by Taiwan biotech Immunwork, confirmed a five-day plasma half-life in first-in-human trials using a dual fatty acid bundle approach not used by any approved ...

The drugmaker said it would accept requests for early access to its experimental drug for some adults with severe obesity.

Medicare patients are getting access to GLP-1s for obesity through the Bridge program. But questions linger regarding ...

Few products have captured public interest as fast as GLP-1 receptor-agonist weight-loss drugs. But one unforeseen consequence of their popularity has been to create what is, in effect, one of the ...

Jordan began her GLP-1 journey the way she approaches most things: methodically. She found Zepbound 1 through social media, researched it with the same attention she brings to her client projects, and ...

Glucagon-like peptide-1 (GLP-1) receptor agonists were originally prescribed for type 2 diabetes (T2D), but several are now specifically approved for long-term weight management. Comparing how well ...

Yale University researchers were able to easily obtain GLP-1 prescriptions online using fake patient profiles, in some instances receiving prescriptions in less than five minutes and with minimal ...

Many telehealth platforms selling GLP-1s online prescribe the drugs without requiring a clinician to interact with the patient in real time, according to a secret shopper study conducted by ...

Albert Bourla, Pfizer Chairman & CEO, discusses strong performance in primary care and the game-changing Metsera acquisition for GLP-1 set to launch by 2028 on 'Mornings with Maria.' Albert Bourla, ...

Some Medicare patients will be able to access to GLP-1 medication for weight loss for the first time starting July 1, paying a $50 monthly copay through a new program designed to make the drugs more ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic or Wegovy, have revolutionized type 2 diabetes and weight-loss management, but they have also led to some unfortunate outcomes. A ...

Please provide your email address to receive an email when new articles are posted on . Results were presented at ASCO Annual Meeting and found significantly lower breast cancer incidence following ...